We are live on ! Find out more
DFTX

Definium Therapeutics
DFTX

195 hedge funds and large institutions have $469M invested in Definium Therapeutics in 2025 Q3 according to their latest regulatory filings, with 39 funds opening new positions, 56 increasing their positions, 48 reducing their positions, and 23 closing their positions.

New
Increased
Maintained
Reduced
Closed

96% more call options, than puts

Call options by funds: $21.3M | Put options by funds: $10.9M

73% more capital invested

Capital invested by funds: $271M → $469M (+$198M)

70% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 23

17% more repeat investments, than reductions

Existing positions increased: 56 | Existing positions reduced: 48

8% more funds holding

Funds holding: 181 → 195 (+14)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

3.09% less ownership

Funds ownership: 55.32% → 52.23% (-3.1%)

Holders
195
Holders Change
+14
Holders Change %
+7.73%
% of All Funds
2.56%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
39
Increased
56
Reduced
48
Closed
23
Calls
$21.3M
Puts
$10.9M
Net Calls
+$10.4M
Net Calls Change
+$7.9M

Top Buyers

1
Goldman Sachs
Goldman Sachs
New York
+$4.18M
2
O
OrbiMed
New York
+$3.43M
3
RA
Rosalind Advisors
Ontario, Canada
+$3.08M
4
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$2.8M
5
Two Sigma Investments
Two Sigma Investments
New York
+$2.24M

Top Sellers

1
CC
Commodore Capital
New York
-$16.6M
2
Marshall Wace
Marshall Wace
United Kingdom
-$9.69M
3
DTC
Deep Track Capital
Connecticut
-$9.33M
4
Blackstone Inc
Blackstone Inc
New York
-$7.56M
5
ABG
Ally Bridge Group
New York
-$3.4M
Name Holding Trade Value Shares
Change 		Change in
Stake
Wellington Management Group
26
Wellington Management Group
Massachusetts
$3.02M -$52.1K -5,587 -2%
N
27
Nuveen
North Carolina
$2.75M -$59.1K -6,338 -3%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$2.7M -$109K -11,708 -5%
Point72 Asset Management
29
Point72 Asset Management
Connecticut
$2.64M +$2.09M +224,300 New
D.E. Shaw & Co
30
D.E. Shaw & Co
New York
$2.55M +$1.47M +157,570 +268%
BCM
31
Boxer Capital Management
California
$1.93M +$1.52M +163,500 New
CP
32
CenterBook Partners
Connecticut
$1.88M +$1.49M +159,421 New
Barclays
33
Barclays
United Kingdom
$1.78M -$230K -24,628 -14%
AI
34
AdvisorShares Investments
Maryland
$1.43M +$113K +12,071 +11%
UBS AM
35
UBS AM
Illinois
$1.38M +$700K +75,110 +178%
Swiss National Bank
36
Swiss National Bank
Switzerland
$1.38M +$18.7K +2,000 +2%
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$1.32M -$29.6K -3,178 -3%
CSS
38
Cubist Systematic Strategies
Connecticut
$1.28M +$1.01M +108,214 New
DP
39
Diadema Partners
New Jersey
$1.25M -$491K -52,645 -33%
DCI
40
Data Collective IV
California
$1.18M – – –
Bank of America
41
Bank of America
North Carolina
$990K -$328K -35,203 -30%
Two Sigma Advisers
42
Two Sigma Advisers
New York
$961K +$760K +81,483 New
RA
43
Royce & Associates
New York
$955K +$756K +81,024 New
SC
44
Stempoint Capital
New York
$906K -$130K -13,977 -15%
LPL Financial
45
LPL Financial
California
$895K +$69.6K +7,458 +11%
PHS
46
PFM Health Sciences
California
$886K +$701K +75,138 New
AllianceBernstein
47
AllianceBernstein
Tennessee
$882K – – –
BFM
48
Boothbay Fund Management
New York
$802K +$466K +50,000 +278%
IC
49
Ikarian Capital
Texas
$739K – – –
Wolverine Trading
50
Wolverine Trading
Illinois
$725K +$562K +60,250 New
1
2
3 4 5

DFTX Hedge Fund Activity: Q3 2025 in Review

195 of the 7,619 institutional investors tracked by Wall St. Rank reported a position in Definium Therapeutics (DFTX) for Q3 2025, worth a combined $469M — up 73% from $271M a quarter earlier.

Buyers outnumbered sellers: 39 funds opened new DFTX positions and 23 closed out — a net gain of 16 holders — while 56 added to existing stakes and 48 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $4.18M. The largest seller was Commodore Capital, cutting an estimated $16.6M.

  • 195 institutional investors held Definium Therapeutics (DFTX) as of Q3 2025, up from 181 in Q2 2025.
  • Funds reported $469M of Definium Therapeutics stock for Q3 2025, up 73% quarter-over-quarter.
  • 39 funds opened new Definium Therapeutics positions in Q3 2025 and 23 closed out, a net change of +16 holders.
  • The largest Definium Therapeutics buyer in Q3 2025 was Goldman Sachs, an estimated $4.18M added.
  • The largest Definium Therapeutics seller in Q3 2025 was Commodore Capital, an estimated $16.6M sold.

Based on aggregated 13F filings for Q3 2025.